本帖最后由 老马 于 2012-1-13 21:20 编辑
; l, S2 _$ o2 l3 X( ^# Z
& h: ~! k- _( T' i2 P+ s7 m爱必妥和阿瓦斯丁的比较6 t5 \: Z/ B; V/ ~
% g4 v/ s" p; S& f* Mhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/& M' v8 h U f; l
3 D/ Z0 i9 o6 O, [
+ }# h0 a5 V! o9 f! R% t9 |http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/+ |) K, i! F: S$ Q
==================================================) e" S. N5 a* o3 g" `. q U( W' H9 p# v
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)) U2 L: G" r, q( ?0 }
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
2 o& f+ L: _! c" HResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
- X) \5 t8 c( F- ^' ~# P
|
显身卡
7 P- m1 u' e$ F/ B* U+ ]
